Us Bancorp \De\ Ideaya Biosciences, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 1,714 shares of IDYA stock, worth $45,489. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,714

Previous 1,025 67.22%

Holding current value

$45,489

Previous $35,000 54.29%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$30.37 - $43.05 $20,924 - $29,661	689 Added 67.22%	1,714 $54,000
Q2 2024 Aug 06, 2024	BUY	$34.37 - $43.46 $2,715 - $3,433	79 Added 8.35%	1,025 $35,000
Q1 2024 May 07, 2024	BUY	$34.2 - $47.13 $19,767 - $27,241	578 Added 157.07%	946 $41,000
Q4 2023 Feb 09, 2024	BUY	$24.59 - $35.83 $2,803 - $4,084	114 Added 44.88%	368 $13,000
Q2 2023 Aug 09, 2023	BUY	$13.33 - $25.53 $173 - $331	13 Added 5.39%	254 $5,000
Q1 2023 May 09, 2023	SELL	$13.49 - $18.72 $458 - $636	-34 Reduced 12.36%	241 $3,000
Q4 2022 Feb 13, 2023	SELL	$14.47 - $18.17 $22,168 - $27,836	-1,532 Reduced 84.78%	275 $4,000
Q3 2022 Oct 27, 2022	BUY	$9.24 - $15.79 $3,003 - $5,131	325 Added 21.93%	1,807 $27,000
Q2 2022 Aug 01, 2022	BUY	$8.28 - $13.88 $11,318 - $18,973	1,367 Added 1188.7%	1,482 $21,000
Q4 2021 Feb 11, 2022	BUY	$20.95 - $26.88 $2,409 - $3,091	115 New	115 $3,000
Q4 2019 Feb 04, 2020	SELL	$5.34 - $9.09 $2,670 - $4,545	-500 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$9.58 - $11.95 $4,790 - $5,975	500 New	500 $5,000

Others Institutions Holding IDYA

# of Institutions

216

Shares Held

80.8M

Call Options Held

69K

Put Options Held

20K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.28B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account